Addex spinoff Neurosterix debuts with $63m for developing neurological therapies
Addex has also sold its preclinical neurological assets and drug discovery platform to Neurosterix for $5.5m and 20% equity.
Addex has also sold its preclinical neurological assets and drug discovery platform to Neurosterix for $5.5m and 20% equity.
What's Your Reaction?
